- cafead   May 06, 2024 at 11:32: AM
via Johnson & Johnson has released results from a Phase II clinical trial evaluating ERLEADA (apalutamide) as an adjuvant therapy with androgen deprivation therapy (ADT) in high-risk localised prostate cancer (HRLPC) patients post-radical prostatectomy (RP).
article source
article source